# 04_QA_REPORT — PP-0201 D2 Lymphadenectomy

## QA Metadata

| Field | Value |
|---|---|
| PP ID | PP-0201 |
| Title | D2 Lymphadenectomy |
| QA Version | 1.0.0 |
| Artifact Version | 1.0.0 |
| Decision Status | APPROVED / LOCKED |
| Governance Standard | CORE_WORKING_RULES v1.7 |
| Gold Specification | FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1 |
| Final Decision | PASS |

## Layer 1 — Content QA

### 1. Scope respected

The package answers one clinical educational question:

> What is D2 lymphadenectomy, how does it extend beyond D1, when is it considered, and what should patients understand about its evidence, risks, and limitations?

**PASS**

### 2. Completeness

The package covers:

- definition;
- anatomy;
- clinical context;
- evidence;
- surgical expertise;
- organ preservation;
- staging;
- minimally invasive context;
- patient questions;
- misconceptions;
- boundaries.

**PASS**

### 3. Internal consistency

D2 is consistently described as an anatomical extent.

The package does not alternate between anatomical and node-count definitions.

**PASS**

## Layer 2 — Clinical QA

### 4. D2 anatomical definition

The package uses the NCCN definition as the primary anchor.

**PASS**

### 5. D1/D2 distinction

D2 is consistently described as D1 plus additional regional nodal territories.

**PASS**

### 6. Vietnamese station framework

The package preserves the supplied Vietnamese terminology and identifies it as source-specific.

It does not invent a universal station crosswalk.

**PASS**

### 7. D2+ boundary

D2+ is acknowledged but not expanded into a second package.

**PASS**

### 8. Evidence interpretation

The package does not overstate D2 survival benefit.

It preserves the distinction between:

- recurrence outcomes;
- gastric-cancer-related mortality;
- overall survival;
- postoperative morbidity/mortality.

**PASS**

### 9. Historical versus modern D2

Historical organ-resection-associated morbidity is clearly distinguished from modern organ-preserving D2.

**PASS**

### 10. Surgical expertise

The package preserves NCCN's emphasis on substantial training and experienced centers.

**PASS**

### 11. Organ preservation

The package explicitly states that:

- routine splenectomy is not part of D2;
- routine prophylactic pancreatectomy is not recommended.

**PASS**

### 12. Node-count safeguard

The package explicitly distinguishes:

- D2 anatomical extent;
- nodes examined;
- nodes positive;
- ≥16-node examination goal.

**PASS**

### 13. Palliative context

The package does not imply that D2 is required for palliative surgery.

**PASS**

### 14. Early gastric cancer

The package does not state that every early gastric cancer requires D2.

It preserves the endoscopic pathway.

**PASS**

### 15. Minimally invasive D2

The package presents minimally invasive D2 as selected-context evidence, not a universal recommendation.

**PASS**

## Layer 3 — Educational QA

### 16. Patient-facing readability

Medical terminology is explained at first use.

**PASS**

### 17. One concept per paragraph

Clinical knowledge is divided into independent blocks.

**PASS**

### 18. Neutral tone

No sensational or promotional wording.

**PASS**

### 19. Uncertainty

Context-dependent claims are explicitly identified as such.

**PASS**

### 20. Misconception handling

The package encodes common misunderstandings:

- D2 is not twice the nodes;
- D2 is not 16 nodes;
- D2 does not automatically mean splenectomy;
- D2 does not automatically mean pancreatectomy;
- D2 is not universally superior to D1.

**PASS**

### 21. Patient questions

Preoperative and postoperative questions are included.

**PASS**

## Layer 4 — Governance QA

### 22. Source-first compliance

The package was produced after searching the project Source Files for:

- exact PP identity;
- clinical evidence;
- adjacent PP boundaries;
- Gold discussion reference;
- Gold specification.

**PASS**

### 23. Approved Decision Batch compliance

The package implements the approved PP-0201 Decision Batch without expanding ownership.

**PASS**

### 24. Gold depth

The package is deliberately substantive across all four artifacts and is not a compact summary.

**PASS**

### 25. Artifact structure

Required artifacts:

- 01_CKO.md
- 02_KNOWLEDGE_PASSPORT.md
- 03_PRIMARY_EVIDENCE_PACKAGE.md
- 04_QA_REPORT.md

**PASS**

### 26. Knowledge graph

Prerequisites, related PPs, and next PP are defined.

**PASS**

### 27. Versioning

All artifacts use semantic version 1.0.0.

**PASS**

### 28. Repository readiness

The package is structured as:

```text
PP-0201_D2_Lymphadenectomy_GOLD_v1.0.0/
├── 01_CKO.md
├── 02_KNOWLEDGE_PASSPORT.md
├── 03_PRIMARY_EVIDENCE_PACKAGE.md
└── 04_QA_REPORT.md
```

**PASS**

## 29. Adjacent-Package Overlap QA

| Adjacent PP | Ownership Check |
|---|---|
| PP-0199 Lymphadenectomy | General framework remains delegated |
| PP-0200 D1 | D1-specific content remains delegated |
| PP-0202 Sentinel Lymph Node | Sentinel methodology excluded |
| PP-0196 Gastrectomy Principles | Gastrectomy principles delegated |
| PP-0197 Subtotal Gastrectomy | Subtotal operation delegated |
| PP-0198 Total Gastrectomy | Total operation delegated |
| PP-0193–0195 | Endoscopic pathway only referenced |
| PP-0203 onward | Treatment interface only |

**PASS**

## 30. Unsupported-Claim QA

The following claims were deliberately excluded:

- D2 always improves overall survival.
- D2 is always superior to D1.
- D2 is always safer.
- D2 is always more dangerous.
- D2 equals ≥16 nodes.
- D2 requires splenectomy.
- D2 requires pancreatectomy.
- D2 is appropriate for every gastric-cancer patient.
- Node count alone identifies D2.

**PASS**

## 31. Clinical Safety QA

The package does not:

- diagnose;
- prescribe;
- select surgery for an individual;
- provide operative instructions;
- provide drug recommendations;
- give individualized prognosis;
- interpret an individual pathology report without the actual report.

**PASS**

## 32. Evidence Traceability QA

High-priority claims are traceable to project sources:

| Claim | Source |
|---|---|
| D2 definition | NCCN |
| D2 station framework | Vietnamese guideline |
| D1/D2 randomized evidence | NCCN |
| Historical morbidity | NCCN |
| Organ-preserving D2 | NCCN |
| Surgical expertise | NCCN |
| Minimally invasive D2 | NCCN |
| Patient-facing experience questions | ACS |
| Palliative distinction | NCCN |
| Nodal staging context | NCI |

**PASS**

## 33. Contradiction QA

The package contains no unresolved internal contradiction.

Source differences are explicitly handled:

- NCCN anatomical definition is the primary definition.
- Vietnamese station terminology is retained as source-specific.
- ACS simplified language does not override the NCCN anatomical concept.

**PASS**

## 34. Gold Depth Integrity QA

### CKO

Contains extensive independent clinical knowledge blocks, patient-facing explanations, misconceptions, key messages, and knowledge graph.

**PASS**

### Knowledge Passport

Contains identity, classification, runtime metadata, evidence hierarchy, safety rules, limitations, and integration information.

**PASS**

### Primary Evidence Package

Contains clinical question, educational intent, scope, primary/supporting sources, hierarchy, evidence matrix, evidence notes, claims summary, consistency review, evidence gaps, update triggers, traceability, and final evidence decision.

**PASS**

### QA Report

Contains all four required QA layers plus overlap, unsupported-claim, traceability, contradiction, and integration checks.

**PASS**

## 35. Boundary QA

The final production boundary is ownership-oriented and non-duplicative.

**Core:** D2-specific.

**Supporting:** contextual evidence.

**Explicitly Excluded:** operative and downstream treatment content.

**Delegated-to PP:** adjacent packages.

**PASS**

## 36. Runtime QA

The runtime can safely answer:

- What is D2?
- How is D2 different from D1?
- Why might D2 be recommended?
- Does D2 mean spleen removal?
- Does D2 mean pancreas removal?
- Why does surgeon experience matter?
- What does ≥16 nodes mean?
- What did D1 versus D2 studies show?
- Can D2 be done laparoscopically?
- What should I ask my surgeon?

The runtime must not answer individualized surgical-selection questions from this package alone.

**PASS**

## 37. Final Quality Decision

# PASS

PP-0201 satisfies the approved Decision Batch and the locked Gold production standard.

The package preserves the central clinical safeguard:

> **D2 is an anatomical lymphadenectomy extent; lymph-node count is a separate pathological/staging measurement.**

It also preserves the central evidence safeguard:

> **D2 cannot be reduced to “more is better”; its clinical value depends on disease context, surgical quality, organ-preservation principles, and experienced care.**

## Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**


## Extended QA

### 38. Decision-to-Artifact Fidelity

The approved Decision Batch identified the core of PP-0201 as:

- D2 anatomy;
- D1/D2 evidence;
- clinical context;
- surgical expertise;
- modern organ preservation;
- staging/node-count distinction;
- patient-facing interpretation.

The four artifacts preserve all of these elements.

**PASS**

### 39. Atomicity QA

The package remains one clinical educational question.

It does not become a generic “all extended lymphadenectomy” package.

**PASS**

### 40. D1 Boundary QA

PP-0200 owns D1-specific content.

PP-0201 uses D1 only to explain the extension into D2.

No substantive D1 duplication detected.

**PASS**

### 41. D2+ Boundary QA

D2+ is acknowledged but not developed into a separate clinical package.

No D2+ operative algorithm is present.

**PASS**

### 42. Sentinel-Node Boundary QA

No sentinel-node mapping, tracer, biopsy, or methodology is presented.

**PASS**

### 43. Gastrectomy Boundary QA

The package does not choose subtotal versus total gastrectomy.

**PASS**

### 44. Endoscopic Boundary QA

EMR/ESD are referenced only to explain that selected early cancers may follow a non-surgical pathway.

No endoscopic criteria or technique is reproduced as a D2 package.

**PASS**

### 45. Treatment Boundary QA

The package discusses postoperative treatment only as an interface.

It does not prescribe chemotherapy, chemoradiation, immunotherapy, or targeted therapy.

**PASS**

### 46. Evidence Hierarchy QA

The package uses:

1. locked governance;
2. approved PP decision;
3. Gold specification;
4. discussion/artifact references;
5. relevant clinical source materials.

Clinical claims are anchored primarily in NCCN and the supplied Vietnamese guideline, with NCI and ACS as support.

**PASS**

### 47. Source Terminology QA

The package does not silently replace the Vietnamese station framework with an invented crosswalk.

It also does not let simplified ACS language redefine D2.

**PASS**

### 48. Clinical Uncertainty QA

The package explicitly distinguishes:

- established;
- supported/context-dependent;
- not established.

**PASS**

### 49. D1/D2 Comparative Evidence QA

The package preserves:

- historical higher morbidity/mortality in Dutch D2;
- lower local/regional recurrence in long-term follow-up;
- fewer gastric-cancer-related deaths;
- no simple OS superiority;
- Italian randomized evidence without significant OS difference;
- importance of modern organ preservation.

**PASS**

### 50. Organ-Preservation QA

The package correctly separates:

**D2**

from

**splenectomy**

and

**pancreatectomy**.

Routine prophylactic organ removal is not presented as part of D2.

**PASS**

### 51. Node-Count QA

The package explicitly rejects:

> D2 = 16 nodes.

It distinguishes:

- anatomical extent;
- nodes examined;
- nodes positive;
- ≥16-node examination goal.

**PASS**

### 52. Minimally Invasive QA

Minimally invasive D2 is presented as selected-context evidence.

The package does not recommend laparoscopic/robotic surgery universally.

**PASS**

### 53. Palliative QA

The package clearly separates curative/resectable D2 from palliative surgery.

**PASS**

### 54. Staging QA

The package explains the relationship between:

- lymphadenectomy;
- node examination;
- positive nodes;
- N category.

It does not become a complete TNM staging package.

**PASS**

### 55. Postoperative Interface QA

The package correctly states that lymphadenectomy extent can influence postoperative treatment context.

It does not turn this into treatment selection.

**PASS**

### 56. Patient-Safety QA

The package does not provide:

- individual surgical advice;
- operative instructions;
- treatment prescriptions;
- individualized prognosis;
- individualized pathology interpretation.

**PASS**

### 57. Educational Depth QA

The CKO contains extensive independent clinical blocks, misconceptions, runtime patterns, and patient questions.

The KP contains retrieval and safety metadata.

The EP contains detailed claim-level evidence analysis.

The QA contains substantive four-layer review plus overlap and traceability checks.

**PASS**

### 58. Gold Depth Integrity QA

The package is not intentionally compacted.

All four artifacts were expanded to preserve the project's non-negotiable Gold-depth requirement.

**PASS**

### 59. Knowledge Graph QA

The hierarchy remains:

**PP-0199 Lymphadenectomy**

↓

**PP-0200 D1 Lymphadenectomy**

↓

**PP-0201 D2 Lymphadenectomy**

↓

**PP-0202 Sentinel Lymph Node**

with downstream treatment packages after surgery.

**PASS**

### 60. Runtime Retrieval QA

The package supports safe responses to:

- definition;
- anatomy;
- D1/D2 comparison;
- evidence;
- risk;
- expertise;
- organ preservation;
- node count;
- minimally invasive context;
- patient questions.

**PASS**

### 61. Runtime Escalation QA

Individualized questions are correctly escalated:

- “Should I have D2?”
- “Was my surgery adequate?”
- “Do I need spleen removal?”
- “Do I need chemotherapy?”
- “What does my exact pathology mean?”

**PASS**

### 62. Versioning QA

All artifacts are v1.0.0.

ZIP name includes PP number, full title, GOLD status, and version.

**PASS**

### 63. Repository QA

Required four artifacts are present.

No extra artifact has been introduced that changes the package specification.

**PASS**

### 64. Evidence Gap QA

Known unsupported areas are explicitly documented rather than filled with general medical knowledge.

**PASS**

### 65. Contradiction QA

No unresolved internal contradiction.

Source-specific differences are documented and calibrated.

**PASS**

### 66. Overclaim QA

Rejected claims include:

- D2 always improves survival;
- D2 is always better;
- D2 is always safer;
- D2 equals ≥16 nodes;
- D2 requires splenectomy;
- D2 requires pancreatectomy;
- D2 is mandatory for every gastric cancer;
- node count proves D2.

**PASS**

### 67. Boundary QA

The production boundary remains ownership-oriented:

**Core = D2-specific**

**Supporting = contextual**

**Explicitly Excluded = operative/downstream**

**Delegated-to PP = adjacent/future owners**

**PASS**

### 68. Final Gold Integrity Statement

The package maintains:

- atomicity;
- source grounding;
- clinical governance;
- evidence traceability;
- patient-facing depth;
- adjacent-package ownership;
- runtime safety;
- maintainability;
- scalable knowledge-graph structure.

**PASS**

## Final Quality Decision

# PASS

PP-0201 satisfies the approved Decision Batch and the locked Gold Population Package production standard.

The two highest-priority safeguards are preserved:

> **D2 is an anatomical lymphadenectomy extent, not a node-count definition.**

and

> **D2 should not be reduced to “more surgery is better”; its value depends on clinical context, evidence, surgical quality, organ preservation, and experienced care.**

## Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
